Skip to main
GILD

Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences (GILD) Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 50%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Gilead Sciences is positioned for a positive financial outlook due to several key developments, including the anticipated launch of Trodelvy for first-line metastatic triple-negative breast cancer in the second half of 2026, which is expected to significantly enhance its oncology pipeline and revenue streams. The company has already exceeded its 90% payer coverage goal six months ahead of schedule and is experiencing strong revenue growth within its HIV franchise, projecting a consistent 6% year-over-year increase moving into 2026. Additionally, the encouraging sales growth of Livdelzi and the robust expansion of the HIV PrEP market, alongside disciplined operating expenses and improving operating margins, suggest the potential for sustained financial strength and resilience for Gilead Sciences.

Bears say

Gilead Sciences has revised its revenue guidance for Veklury, reducing its forecast for FY25 to $1 billion from $1.4 billion, and predicts a further decline to $600 million by 2026, indicating a significant and ongoing downward trend in sales. The cell therapy segment is also under pressure, with a reported revenue decline of 6% year-over-year, and Gilead expects a 10% year-over-year decrease in this category for 2026 due to increasing competition and policy-related challenges. Additionally, the overall sales trajectory from Veklury has become less impactful on total revenues, reflecting a shift in Gilead's business landscape as competitive pressures mount and revenue declines continue to affect performance.

Gilead Sciences (GILD) has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 50% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gilead Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gilead Sciences (GILD) Forecast

Analysts have given Gilead Sciences (GILD) a Buy based on their latest research and market trends.

According to 16 analysts, Gilead Sciences (GILD) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $148.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $148.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gilead Sciences (GILD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.